All Points of the Pharma Compass

With major therapeutic indications close on the horizon, the industry must urgently address the prohibitive costs and manufacturing complexities currently blocking patient access to life-changing cures. Credit: Music from #Uppbeat (free for Creators!):https://uppbeat.io/t/roo-walker/over-the-horizonLicense code: JDOYSHIQBT8JRFSV

Technological innovations are allowing for improvements in the clinical trial sector and providing greater volumes of data; however, companies should be mindful to ensure they are measuring meaningful data. In this latest episode of All Points of the Pharma Compass, we chat with Mikesh Udani from Albus Health to find out more about the innovations shaping the clinical trials sector. Music from #Uppbeat (free for Creators!):uppbeat.io/t/roo-walker/over-the-horizonLicense code: G3VNPEBBOP2ZU1CF

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.Music from #Uppbeat (free for Creators!):uppbeat.io/t/roo-walker/over-the-horizonLicense code: G3VNPEBBOP2ZU1CF

Non-invasive drug delivery via pulmonary and nasal routes is increasingly in demand; however, while there has already been significant innovation within the sector, even more is required to meet future needs.Music from #Uppbeat (free for Creators!):uppbeat.io/t/roo-walker/over-the-horizonLicense code: SEVYSTJFQJ4MEGXU

In a review of CPHI Frankfurt 2025, several event exhibitors chat about the trends making waves in the industry and highlight the importance of face-to-face collaborations and networking.Music from #Uppbeat (free for Creators!):uppbeat.io/t/roo-walker/over-the-horizonLicense code: XQ4BQIXL56OESJJQ